2008;93:3266 81. S5.4-6. Funder JW, Carey RM, Mantero F, et al. The management of pri- mary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889 916. S5.4-7. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associ- ated with resistant hypertension. Hypertension. 2011;58:811 7. S5.4-8. Kump K, Whalen C, Tishler PV, et al. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J. Respir Crit Care Med. 1994;150:735 41. S5.4-9. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540 5. S5.4-10. Grossman E, Messerli FH. Drug-induced hypertension: an unap- preciated cause of secondary hypertension. Am J Med. 2012;125: 14 22. S5.4-11. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guide- line. J Clin Endocrinol Metab. 2014;99:1915 42. S5.4-12. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guide- line. J Clin Endocrinol Metab. 2008;93:1526 40. S5.4-13. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommenda- tions of the European Society of Hypertension. J Hypertens. 2009;27:1719 42. S5.4-14. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sam- ple. Br Med J. 1976;2:554 6. S5.4-15. Hassan-Smith Z, Stewart PM. Inherited forms of mineralo- corticoid hypertension. Curr Opin Endocrinol Diabetes Obes. 2011;18:177 85. S5.4-16. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933 51. 5.4.1. Drugs and Other Substances With Potential to Impair BP Control S5.4.1-1. 